Page last updated: 2024-09-05

cilengitide and Cancer of Prostate

cilengitide has been researched along with Cancer of Prostate in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Al-Hawary, M; Bradley, DA; Chen, A; Cooney, KA; Daignault, S; Dipaola, RS; Doyle, G; Escara-Wilke, J; Gross, ME; Hussain, M; Keller, ET; Mathew, P; Pienta, KJ; Ryan, CJ; Small, E; Smith, DC; Stein, MN	1
Agus, D; Alva, A; Carducci, M; Chen, A; Cooney, K; Daignault, S; Dipaola, R; Hussain, M; Pienta, K; Slovin, S; Smith, DC	1
Beekman, KW; Colevas, AD; Cooney, K; Dipaola, R; Dunn, RL; Gross, M; Hussain, M; Keller, ET; Pienta, KJ; Ryan, CJ; Smith, D	1

Trials

2 trial(s) available for cilengitide and Cancer of Prostate

Article	Year
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational new drugs, 2011, Volume: 29, Issue:6 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Collagen Type I; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Snake Venoms; Time Factors; Treatment Outcome	2011
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Infusions, Intravenous; Integrin alphaVbeta3; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Vitronectin; Snake Venoms; Time Factors; Treatment Failure; United States	2012

Article

Year

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Investigational new drugs, 2011, Volume: 29, Issue:6

Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Collagen Type I; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Snake Venoms; Time Factors; Treatment Outcome

2011

Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.

Investigational new drugs, 2012, Volume: 30, Issue:2

Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Infusions, Intravenous; Integrin alphaVbeta3; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Vitronectin; Snake Venoms; Time Factors; Treatment Failure; United States

2012

Other Studies

1 other study(ies) available for cilengitide and Cancer of Prostate

Article	Year
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clinical genitourinary cancer, 2006, Volume: 4, Issue:4 Topics: Androgens; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Integrins; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Snake Venoms	2006